News

Q3 2025 Earnings Call Transcript August 13, 2025 Organigram Global Inc. misses on earnings expectations. Reported EPS is ...
Organigram's Q3 sales rose 72% to $51.14 million, driven by Motif acquisition and global demand, with margin gains and positive cash flow expected.
Organigram is a licensed cannabis producer based in Moncton, New Brunswick. It partnered with British American Tobacco in 2023 to develop new cannabis products and also bought The Edibles and ...
OrganiGram (OGI) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.02 per share a year ago. These figures are ...
Analysts expect OrganiGram Holdings to report an earnings per share (EPS) of $-0.01. The announcement from OrganiGram Holdings is eagerly anticipated, with investors seeking news of surpassing ...
TORONTO, February 04, 2025--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of ...
Accelerates Organigram’s R&D and product pipeline development, provides meaningful capital injection of ~C$221 million and strengthens Organigram’s ability to compete in existing markets and ...
Organigram Maintains Strong Cash Position Prior to the Equity Top-Up, Organigram e njoyed a strong cash position of CA$168 million reported as at the end of Fiscal Q1-2022 (November 30, 2021).
Organigram also inked a deal with Serbia-based Eviana to purchase up to 25% of its hemp-derived CBD oil. The company views this agreement as a key part of its strategy to serve the broader ...